Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-420-0 | CAS number: 7605-52-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 4 April - 29 July 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Study in accordance with recognised test method
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF, 12 Nohsan No. 8147
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
Test animals
- Species:
- rat
- Strain:
- other: CD (Crl:CD ‘SD’)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 196-268 g
- Fasting period before study: overnight
- Housing: solid bottomed polycarbonate cages with a stainless steel mesh lid
- Diet (e.g. ad libitum): standard rodent diet (Rat and Mouse No. 1 Maintenance Diet)
- Water (e.g. ad libitum): potable water taken from the public supply was freely available via polycarbonate bottles fitted with sipper tubes
- Acclimation period:at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 23°C
- Humidity (%): 40 to 70%
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): artificial lighting was controlled to give a cycle of 12 hours continuous light and 12 hours continuous dark per 24 hours
IN-LIFE DATES: From: 4 April 2008 To: 13 May 2008
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 30mg/l and 200 mg/l
- Amount of vehicle (if gavage): 10 ml/kg
- Justification for choice of vehicle: not specified
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
DOSAGE PREPARATION (if unusual):
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The dose levels for the study were chosen in compliance with the study guidelines. As no previous toxicological information was available the initial dose level was 300 mg/kg. - Doses:
- 300 mg/kg or 2000 mg/kg
- No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days (or other?) 14 days
- Frequency of observations and weighing: Animals were observed soon after dosing and at frequent intervals for the remainder of Day 1. On subsequent days, surviving animals were observed once in the morning and again at the end of the experimental day (with the exception of Day 15 - morning only). The nature and severity, where appropriate, of the clinical signs and the time were recorded at each observation.The weight of each rat was recorded on Days 1 (prior to dosing), 8 and 15 or at death. Individual weekly bodyweight changes and group mean bodyweights were calculated.
- Necropsy of survivors performed: All animals were subject to a macroscopic examination which consisted of opening the cranial, thoracic and abdominal cavities. The macroscopic appearance of all examined organs was recorded.
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: mortality, clinical observations, bodyweight
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 300 - <= 2 000 mg/kg bw
- Mortality:
- One female dosed at 2000 mg/kg bodyweight was found dead at the first observation period on Day 2 and another female dosed at this level was found dead at the second observation period on Day 2.
- Clinical signs:
- Clinical signs prior to death in both animals comprised hunched posture, unsteady gait, piloerection, increased breathing, irregular breathing, reduced body tone, underactivity, flat posture, prostrate posture, lachrymation, reduced body temperature, shallow breathing, red staining in urine (one animal only) and partially closed eyelids. In addition, one female also showed yellow/brown staining in the perigenital area, along with uncoordinated gait.
- Body weight:
- A loss in bodyweight was recorded for both decedents.
- Gross pathology:
- Macroscopic examination revealed in both animals congestion (darkened tissues/organ) of the subcutaneous tissue, heart, lungs, liver (one animal only), spleen, kidneys and duodenum, enlarged stomach and urinary bladder (one animal only) atrophy of the caecum, yellow fluid contents in the stomach and small intestines and red fluid contents in the large intestines
- Other findings:
- Clinical signs of reaction to treatment in the surviving female treated at 2000 mg/kg bodyweight comprised hunched posture, unsteady gait, piloerection, increased breathing, underactivity, flat posture, muscle tremors, reduced body temperature, yellow/brown staining in the perigenital area, prominent eyes and thin build. All of these signs had resolved as judged by external appearance, by Day 10.
Clinical signs seen in females dosed at 300 mg/kg bodyweight comprised unsteady gait seen in five animals and loose faeces were noted in two animals. These signs had all resolved as judged by external appearance, by Day 2.
Low bodyweight gains were noted for three surviving animals dosed at 2000 mg/kg bodyweight and one animal dosed at 300 mg/kg bodyweight, all on Day 15. All other surviving animals were considered to have achieved satisfactory bodyweight gains throughout the study.
The macroscopic examination of surviving animals terminated on Day 15 revealed atrophy of the stomach in one female dosed at 2000 mg/kg bodyweight. No abnormalities were noted in the other surviving animals at the macroscopic examination at this time.
Applicant's summary and conclusion
- Conclusions:
- The acute median lethal oral dose (LD50) to rats of M3MC-Carboxylate was demonstrated to be between 300 and 2000 mg/kg bodyweight.
M3MC-Carboxylate is included in Category 4, according to the Globally Harmonised System (GHS), (UNITED NATIONS, 2005). - Executive summary:
The acute median lethal oral dose (LD50) to rats of M3MC-Carboxylate was demonstrated to be between 300 and 2000 mg/kg bodyweight. M3MC-Carboxylate is included in Category 4, according to the Globally Harmonised System (GHS), (UNITED NATIONS, 2005).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.